TA
Tata India Pharma & Healthcare Fund Direct Growth
Latest NAV
+7.91% 1Y
Sign In to Add to Portfolio
Benchmark: BSE Healthcare TRI
Expense ratio
1.00%
AUM
₹1,565 Cr
Min SIP
₹100
Min lump sum
₹5,000
1Y
+7.91%
3Y (ann.)
+18.26%
5Y (ann.)
+14.01%
Launched
Dec 2015
Where the NAV sits & how risky it is
₹38.06
52-week range
at 71%
₹38.06
Low 02 Apr 2026₹32.80
High 11 Aug 2026₹40.16
Risk level
Very High
Low
Very high
NAV history
29 Dec 2015
Since inception
01 Oct 2026
Returns by period
1W
-3.56%
1M
-4.29%
3M
-0.15%
6M
+15.20%
1Y
+7.91%
3Y
+18.26%
5Y
+14.01%
3Y and 5Y returns are annualised.
Return calculator
You invest
—
Est. gain
—
Est. value
—
Invested Gain
Invested
Projected value
min SIP ₹100
Estimate only. It assumes the selected past return repeats every year; 3Y and 5Y figures are taken as annualised. Actual returns vary and are not guaranteed.
Where your money goes
AS OF 31 MAY 2026
Equity 99.30%
Cash & other 0.70%
Sector split
Country split
Top 5 hold 31.6%
Top 10 hold 53.3%
40 equity holdings
Equity holdings
(top 30)
| # | Holding | Sector | Country | Weight | YTD |
|---|---|---|---|---|---|
| 1 | Sun Pharmaceutical
INE044A01036 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
9.38%
|
+4.66% |
| 2 | Healthcare Global Enterprises
INE075I01017 |
Healthcare Medical Care Facilities |
India |
5.87%
|
-4.56% |
| 3 | Divis Laboratories
INE361B01024 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
5.80%
|
+2.01% |
| 4 | Abbott
INE358A01014 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
5.41%
|
-11.18% |
| 5 | Cipla
INE059A01026 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
5.18%
|
-7.30% |
| 6 | Max Healthcare Institute
INE027H01010 |
Healthcare Medical Care Facilities |
India |
4.80%
|
-3.60% |
| 7 | Apollo Hospitals
INE437A01024 |
Healthcare Medical Care Facilities |
India |
4.56%
|
+18.83% |
| 8 | Rainbow Childrens Medicare
INE961O01016 |
Healthcare Medical Care Facilities |
India |
4.52%
|
+1.36% |
| 9 | Dr Reddys Laboratories
INE089A01031 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
4.02%
|
+0.33% |
| 10 | Mankind Pharma
INE634S01028 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.77%
|
+7.33% |
About this scheme
The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Fund manager(s): Rajat Srivastava
Exit load: Exit load of 0.25% if redeemed within 30 days.
Scheme snapshot
VR Rating
MS Rating
Plan
Growth
Type
DIRECT
Inception
28 Dec 2015
Lump-sum min
₹5,000
SIP
Purchase
Switch
STP
SWP
Similar schemes
RANKED BY 1Y RETURN
Nippon India Taiwan Equity Fund Direct Growth
1▲ 113.6 pts ahead of this fund
Franklin Asian Equity Fund Direct Growth
2▲ 25.5 pts ahead of this fund
Nippon India Japan Equity Fund - Direct Plan - Growth Plan - Bonus Option
3▲ 22.7 pts ahead of this fund
Nippon India Japan Equity Fund Direct Growth
4▲ 22.7 pts ahead of this fund
Bank of India Small Cap Fund Direct Growth
5▲ 21.3 pts ahead of this fund
TRUSTMF Small Cap Fund Direct Growth
6▲ 21.2 pts ahead of this fund